Hepatitis C patients and Nihon Pharmaceutical Co. reached a deal Sunday to end a series of damages suits over tainted blood products that infected the patients with a hepatitis virus.
Signing the agreement, Tsutomu Miura, Nihon Pharmaceutical president, told the patients, “I sincerely apologize to you that we could not prevent the outbreak and spread of damage. As a drug maker we are deeply reflecting on this in order to support patients and protect people’s lives.”
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.